MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has
Highlights Study achieves enrolment target Study to formally close to new enrolments on 31 July Study results support further clinical development as MRI imaging agent
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, is pleased to announce it has appointed Isaac
Australasian Biotechnology | Vol 33 Number 1 Imagion authored a white paper, published in the April issue of Australasian Biotechnology, discussing current medical imaging technologies,
Imagion Biosystems’ Chairman’s address to shareholders at the 2023 Annual General Meeting. PDF of the 2023 AGM Presentation Deck Watch the AGM 2023 Q&A Session
Video Transcript: Robert Proulx, Imagion Biosystems’ President & CEO: [00:00:00] On April 24th, we sent out the notice of meeting for our annual general meeting
We’re on a mission to make cancer more detectable.
